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Background: Since aggressive cancer cells highly express the CD44 receptor compared to normal cells, hyaluronic
acid (HA) can be used for CD44 targeting molecule. Since glutathione (GSH) level is normally elevated in the
intracellular compartment and in the tumor cell, the fact that disulfide bond can be cleaved by GSH is widely used
for intracellular drug delivery.
Methods: HA was connected with poly(DL-lactide-co-glycolide) (PLGA) using disulfide linkage, and then a diblock
copolymer (HAssLG) was prepared. Doxorubicin (DOX)-loaded HAssLG nanoparticles were prepared by dialysis
procedures.
Results and Discussion: DOX-loaded HAssLG nanoparticles have spherical shapes with small particle size of less
than 300 nm. In fluorescence measurement, DOX was dose-dependently liberated from nanoparticles by the
addition of GSH. DOX release rate from HAssLG nanoparticles was increased by the addition of GSH. To confirm
CD44 receptor-mediated endocytosis of nanoparticles, CD44-positive MDA-MB231 cells were employed and
fluorescence intensity was strong when nanoparticles were treated to tumor cells. However, fluorescence intensity was
significantly decreased through blocking of the CD44 receptor by pretreatment of cells with free HA. Fluorescence
intensity of cells was increased again when GSH was added, indicating that HAssLG nanoparticles have CD44 receptor
targetability and potential of redox-responsive drug delivery. For animal imaging study, CD44-positive MDA-MB231 cells
and CD44-negative NIH3T3 cells were simultaneously implanted into the right flank and left flank of mice, respectively.
Fluorescence intensity was significantly stronger at tumor mass of MDA-MB231 cells than solid mass of NIH3T3 cells,
indicating that HAssLG nanoparticles were specifically delivered to tumor cells.
Conclusions: The results indicated that HAssLG nanoparticles have specificity against the CD44 receptor and can
be used for anticancer drug targeting. We recommend HAssLG nanoparticles as a promising vehicle for cancer
drug targeting.
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Nanomedicines based on nanotechnology have been ex-
tensively investigated for drug delivery issues, and they
can be considered as appropriate vehicles for tumor tar-
geting due to their small sizes [1–4]. Especially, nanosized
vehicles such as nanoparticles or polymeric micelles have
superior potentials for solid tumor targeting because the
enhanced permeation and retention (EPR) effect against
tumor blood vessels is regarded as a preferential advantage
of nanovehicles for solid tumor targeting [5, 6]. Further-
more, nanoparticles can be decorated with various target-
ing moieties for specific targeting of cancer cells since
they have a big surface area [7–10]. Due to these intrinsic
properties, nanoparticles can concentrate cytotoxic anti-
cancer drug to the solid tumor with minimal unwanted
side effects for normal tissues/cells. From these points of
view, nanoparticles decorated with targeting moieties have
been also extensively investigated [7–10].
Aggressive tumor cells frequently overexpress the CD44
receptor in the cell membrane [11–18]. This is a specific
receptor for hyaluronic acid (HA), and HA is known to
stimulate spreading, migration, invasion, and metastasis of
cancer cells [11–14, 17]. From these reasons, hyaluronic
acid has been extensively used as a vehicle for specific tar-
geting of the CD44 receptor of tumor cells [8, 18–22].
Especially, Prestwich’s group extensively investigated the
potential of CD44 receptor delivery of HA-anticancer
agent conjugates against cancer cells [19–22]. Further-
more, HA was also investigated for tissue engineering,
gene delivery, and peptide delivery due to the biodegrad-
ability and biocompatibility [23–25].
Nanoparticles based on redox-responsive drug targeting
for cancer cells also have been extensively investigated in
the last decades [26–29]. Redox-responsive drug delivery is
based on the fact that disulfide bond can be reduced by
glutathione and intracellular glutathione (GSH) level is sig-
nificantly higher than the extracellular fluid level [30]. This
peculiar property between GSH and disulfide bond stimu-
lated the redox-responsive drug delivery concept. For ex-
ample, Sun et al. synthesized a poly(ethylene glycol)/poly
(ε-caprolactone) block copolymer using disulfide bond [27].
They showed that drug release rate was increased by the
addition of dithiothreitol (DTT) and enhanced tumor cell
uptake of anticancer drugs was observed. Furthermore,
redox-responsive delivery of DNA drugs using disulfide-
linked polymer nanovehicles was also investigated by sev-
eral authors [26–29]. In spite of successful development of
the redox-responsive drug delivery system, GSH levels in
normal tissues and low specificity of nanoparticles are still
obstacles for efficient drug targeting. For example, GSH
levels can be increased in the tissues of a tumor-bearing
mice compared to a normal mice [30]. Therefore, multiple
targeting strategies are required to attain efficient targeting
of tumors.In this study, we synthesized a HA-b-PLGA (HAssLG)
copolymer having disulfide linkage between HA and
PLGA for targeting of tumor cells through the CD44 re-
ceptor and redox-responsive process. Since PLGA is a
biodegradable and lipophilic polymer, PLGA must form
the core of the nanoparticles while HA would form the
outer shell of the nanoparticles. We studied the potential
of CD44 receptor-mediated and redox-responsive target-
ing of tumor cells by HAssLG nanoparticles using tumor
cells and fibroblast cells in vitro and in vivo.
Methods
Materials
HA (molecular weight from the manufacturer’s data,
7460 g/mol) was purchased from Lifecore Biomedical
(Chaska, MN, USA). Triethylamine (TEA), L-glutathione
(GSH), sodium cyanoborohydride, N-(3-dimethylaminopro-
pyl)-N′-ethylcarbodiimide hydrochloride, and cystamine
hydrochloride were purchased from Sigma Chem. Co. (St.
Louis, USA). N,N′-dicyclohexyl carbodiimide (DCC) and
N-hydroxysuccimide (NHS) were purchased from Sigma-
Aldrich Chemical Co, USA. The dialysis membranes
(Spectra/Pro™ membranes) with molecular weight cutoffs
(MWCO) of 2000 and 12,000 g/mol were purchased from
Spectrum Labs. Doxorubicin (DOX) HCl was purchased
from LC Labs Co. Ltd. (Woburn, MA, USA). Dichlorometh-
ane (DCM) and dimethyl sulfoxide (DMSO) were of HPLC
grade or extra-pure grade. PLGA (PLGA-5005, MW=
5000 g/mol) was purchased from Wako Pure Chemicals Co.
(Osaka, Japan). The molecular weight (MW) of PLGA was
measured by GPC, as described previously [8]. The weight
average MW, number average MW, and polydispersity of
PLGA were 4920, 4780, and 1.029, respectively.
Synthesis of HAssLG Block Copolymer
HA having disulfide linkage in the end of the chain was
synthesized as described by Maruyama et al. [25] with
brief modification. HA (400 mg) was dissolved in 10 ml
of H2O/DMSO (3/7, v/v) solution, and then excess
amount of sodium cyanoborohydride was added to this
solution followed by magnetic stirring for 12 h at room
temperature. After that, 10 equivalents of cystamine
were added and the mixtures were further stirred for 24 h.
The resulting solution was put into a dialysis membrane
(MWCO, 2000 g/mol), and by-products were removed by
dialysis procedure for 2 days followed by lyophilization for
3 days.
NHS-activated PLGA (PLGA-NHS) was separately pre-
pared. Five hundred milligrams of PLGA was dissolved in
DCM with 1.2 equivalents of DCC and NHS. This solution
was stirred for 12 h, and then reactants were precipitated
into the excess amount of methanol followed by filtration
under reduced pressure. The white solid was washed with
methanol three times followed by vacuum drying for a day.
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lows: 400 mg HA-cystamine conjugates and 250 mg of
PLGA-NHS were simultaneously dissolved in dry DMSO
and stirred in nitrogen atmosphere for 2 days. After that,
this solution was then introduced into a dialysis mem-
brane (MWCO, 12,000 g/mol) to remove the unreacted
HA and organic solvent. During the dialysis procedure,
water was exchanged at 3-h intervals for 2 days and then
the resulting solution was lyophilized for 3 days. The ly-
ophilized solid was precipitated into DCM to remove
unreacted PLGA for three times, and then filtered pre-
cipitates were dried under a vacuum for 3 days. The
yield of the final product was 81 % (w/w). Yield of prod-
uct (%, w/w) = [(weight of final product)/(weight of ami-
nated HA + PLGA-NHS)] × 100.1H Nuclear Magnetic Resonance Spectroscopy
1H nuclear magnetic resonance (NMR) spectroscopy
(500 MHz superconducting FT-NMR spectrometer,
Unity-Inova 500, Varian Inc., Agilent Tech., CA, USA)
was employed to confirm synthesis of polymers.Preparation of HAssLG Nanoparticles
Empty or DOX-incorporated nanoparticles were fabri-
cated as follows (Table 1): 50 mg of HAssLG block co-
polymer was dispersed in 1 ml of deionized water and
then mixed with 3 ml DMSO. DOX·HCl was separately
dissolved in 1 ml DMSO with trace amounts of TEA,
and then this solution was added to the polymer/DMSO
solution. Then, the mixed solution was dialyzed against
deionized water using a dialysis membrane (2000 g/mol)
with exchange of water (2-h intervals) for 1 day. After
that, the resulting solution was analyzed or lyophilized.
Empty nanoparticles were fabricated except DOX. To
measure DOX contents in the HAssLG nanoparticles,
5 mg of DOX-loaded nanoparticles was dissolved in
10 ml of DMSO/water mixtures (8/2, v/v) and then ap-
propriately diluted with DMSO. The DOX contents in
the nanoparticles were evaluated with a UV spectropho-
tometer (UV spectrophotometer 1601, Shimadzu Co.,
Japan) at 486 nm. To avoid interference of the polymer,
empty HAssLG nanoparticles were used as blank. Drug
contents were calculated with the following equation:
[(drug weight in the nanoparticle)/(total weight of the
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Transmission electron microscopy (TEM, JEOL JEM-2000
FX II, Japan) was used to observe the morphology of nano-
particles. One drop of nanoparticle solution (0.1 mg/ml)
was dropped onto a carbon film coated on a copper grid
and then dried in room temperature. Three hours later,
phosphotungstic acid (0.05 %, w/w) was then dropped onto
nanoparticles for negative staining and dried in room
temperature for more than 6 h. Observation of nanoparti-
cles was performed at 80 kV.
Particle size was measured with dynamic laser scatter-
ing (DLS-7000, Otsuka Electronics Co., Japan) (nanopar-
ticle concentration, 0.1~1 mg/ml).
Drug Release Study
DOX release from HAssLG nanoparticles was performed
as follows: 10 mg of DOX-incorporated nanoparticles
was dispersed in 5 ml of phosphate-buffered saline (PBS,
0.1 M, pH 7.4), and this solution was put into a dialysis
membrane (MWCO, 12,000 g/mol). After that, the dialy-
sis membrane was introduced into 95 ml PBS in a bottle.
Drug release was performed in a shaking incubator with
100 rpm of stirring speed at 37 °C. Whole media were
replaced with fresh media at specific time intervals. The
released DOX was measured with a UV spectrophotom-
eter (UV spectrophotometer 1601, Shimadzu Co., Japan)
at 486 nm.
Cell Culture
MDA-MB231 human breast carcinoma cells and NIH3T3
mouse fibroblast cells were obtained from Korea Cell Line
Bank Co. (KCLB, Seoul, Korea). MDA-MB231 human
breast carcinoma cells and NIH3T3 mouse fibroblast
cells were maintained in RPMI1640 and DMEM supple-
mented with 10 % fetal bovine serum (5 % CO2 at 37 °C),
respectively.
Cell viability test was performed as follows: MDA-MB231
(1 × 104 cell/well) cells were seeded into 96-well plates and
then incubated overnight (5 % CO2 at 37 °C). DOX or
nanoparticles were treated to these cells. The CD44 recep-
tor of the cells was blocked with 10 equivalents of free HA
1 h before nanoparticle treatment, and then the cells were
washed with PBS. After that, DOX or nanoparticles were
added to the cells in the 96-well plates and incubated in a
CO2 incubator (5 % CO2 at 37 °C) for 4 or 24 h. After that,
media were discarded and then replaced with 100 μl of
fresh media. To this solution, 30 μl of MTT (5 mg/ml) was
added, and then the solution was further incubated in a
CO2 incubator (5 % CO2 at 37 °C) for 4 h. Since the con-
tents of the generated formazan were proportional to the
number of viable cells, the generated formazan was solubi-
lized with DMSO and determined with an automated
computer-linked microplate reader (Molecular Device Co.,
USA) (560 nm test/630 nm reference).
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Cells
Cellular uptake of DOX-loaded HAssLG nanoparticles
was studied with fluorescence microscopy observation and
flow cytometry analysis. MDA-MB231 cells were seeded
onto a cover glass and incubated overnight in a CO2 incu-
bator (5 % CO2 at 37 °C). Then, nanoparticles were treated
to cells for 1 h in a CO2 incubator. One hour before the
addition of nanoparticles, the CD44 receptor was blocked
by pretreatment of free HA (10 equivalents of nanoparticle
contents). Following this, cells were washed with PBS
(pH 7.4, 0.1 M) and fixed with 4 % paraformaldehyde. This
was fixed with immobilization solution (IMMU-MOUNT,
Thermo Electron Corporation, Pittsburgh, PA, USA). Cells
were then observed with a confocal laser scanning micro-
scope (CLSM, TCS-SP2; Leica, Wetzlar, Germany).
For flow cytometry analysis of cells, 1 × 106 cells were
seeded in each well of six-well plates. Nanoparticles were
treated to the cells and incubated for 1 h in a CO2 incu-
bator. One hour before the addition of nanoparticles,
the CD44 receptor was blocked by pretreatment of free
HA (10 equivalents of nanoparticle contents). Cells were
washed with PBS (pH 7.4, 0.1 M) and trypsinized to har-
vest cells. The cells were analyzed with flow cytometery
(FACScan) at an excitation wavelength of 488 nm and
emission wavelength of 522 nm for DOX fluorescence
intensity.
Near-Infrared Absorption Dye Conjugation
A near-infrared (NIR) dye was conjugated with HAssLG
for in vivo animal imaging studies. Fifty milligrams of
HAssLG in 5 ml DMSO/water mixtures (4/1, v/v) was
mixed with 3 mg of sulfo-cyanine7 amine (Lumiprobe
Co., Florida, USA) with 1.2 equivalent moles of EDAC
and NHS. This solution was then stirred for 24 h in
room temperature. After that, the solution was dialyzed
to remove unreacted dye with exchange of water at in-
tervals of 2 h until the dye was not detected in the water.
The detection of the dye and the contents in the polymer
were measured with a UV spectrophotometer (UV-1601
UV-VIS spectrophotometer, Shimadzu, Kyoto, Japan) at
750 nm. The content of the NIR dye was 2.8 %, w/w. (Dye
content (%, w/w) = (dye amount in the nanoparticles/total
weight of the nanoparticles) × 100).
In Vivo Fluorescence Imaging
For fluorescence imaging of the biodistribution of nano-
particles, 1 × 106 MDA-MB231 cells and 1 × 106 NIH3T3
cells were implanted into the right flank and left flank of
nude BALb/C mice (5 weeks, 20 g), respectively. After
20 days, NIR-dye-conjugated nanoparticles were admin-
istered intravenously (i.v.) into the tail vein of mice at a
dose of 20 mg/kg (injection volume was 100 μl). Mice
were observed with a Maestro™ 2 small-animal imaginginstrument (Cambridge Research and Instruments, Inc.,
Woburn, MA, USA). Twenty-four hours later, mice were
sacrificed to evaluate organ distribution of nanoparticles
with the Maestro™ 2 small-animal imaging instrument.
All animal studies were performed under the guidelines
of the Committee of Care and Use of Laboratory Ani-
mals of Chonnam National University.
Results
Characterization of HAssLG Block Copolymer
HA and PLGA were linked with cystamine linkage, and
the block copolymer was synthesized as shown in Fig. 1.
Prior to PLGA conjugation, cystamine was conjugated in
the end of the HA chain by treatment with sodium cya-
noborohydride because polysaccharides have one reduc-
tive end. To this, excess amount of cystamine was added
to make aminated end of HA having disulfide linkage.
Intrinsic peaks of HA were confirmed at 1.6~4.6 ppm at
1H NMR spectra. The ethylene proton of cystamine link-
age was observed at 2.9 ppm as shown in Fig. 1. To the
terminal amine of HA, PLGA was conjugated to construct
the block copolymer having disulfide linkage. The specific
proton peaks of PLGA were observed at 1.2~1.6 ppm and
4.6~5.2 ppm. The final yield of the HAssLG block copoly-
mer was approximately 81 % (w/w).
Characterization of Nanoparticles
Generally, diblock copolymers composed of a hydro-
philic domain and hydrophobic domain can form core-
shell-type nanoparticles in the aqueous environment.
Since HA is the hydrophilic one, it would form the outer
shell of the nanoparticles while PLGA would form the
core of the nanoparticles. Nanoparticles of the HAssLG
block copolymer were fabricated in water by dialysis
procedure. The morphology of empty HAssLG nanopar-
ticles was a spherical shape as shown in Fig. 2a, and
their sizes were less than 200 nm. Particle sizes were in-
creased when DOX was incorporated into the nanoparti-
cles as shown in Fig. 2b, d. DOX-loaded nanoparticles
also have spherical shapes (Fig. 2b) and unimodal size
distribution (Fig. 2c).
To study redox-response properties of nanoparticles,
DOX-loaded nanoparticles were incubated at 37 °C with
and without GSH as shown in Fig. 3a. DOX-loaded nano-
particles were treated with GSH for 4 h, and then fluores-
cence intensity of DOX was measured using a microplate
reader and observed with imaging equipment as shown in
Fig. 3a. As shown in Fig. 3a, fluorescence intensity rapidly
increased according to the increase of GSH concentration.
Furthermore, fluorescence emission spectra of DOX-
loaded nanoparticles were recorded at 520~700 nm as
shown in Fig. 3b. Fluorescence intensity was gradually in-
creased according to the GSH concentration, indicating
that DOX-incorporated HAssLG nanoparticles responded
Fig. 1 Synthesis scheme of HAssLG block copolymer
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by GSH content. Furthermore, DOX release rate was in-
creased when GSH was added to release media as shown
in Fig. 3c. These results indicated that HAssLG nanoparti-
cles have redox-responsive characters and delivery of anti-
cancer drugs would be prompted according to the
concentration of GSH.
CD44 Receptor-Mediated Targeting of HAssLG
Nanoparticles
To investigate CD44-mediated delivery of HAssLG nano-
particles, CD44 receptor-overexpressed MDA-MB231 cells
were employed. Since DOX itself expresses strong fluores-
cence intensity, DOX-loaded HAssLG nanoparticles were
treated to MDA-MB231 cells as shown in Fig. 4a. Asshown in Fig. 4a, red fluorescence of MDA-MB231 cells
was strongly expressed when DOX-loaded nanoparticles
were treated. However, fluorescence intensity was signifi-
cantly decreased when the CD44 receptor was blocked by
pretreatment with free HA as shown in Fig. 3a, indicat-
ing that HAssLG nanoparticles can target tumor cells
through receptor-mediated endocytosis using the CD44
receptor. However, fluorescence intensity was slightly
increased when GSH was added to the cell culture even
though the CD44 receptor was blocked. These results
indicate that HAssLG nanoparticles are responsive to
both the CD44 receptor and redox environment. Further-
more, flow cytometry analysis of cells also supported these
results, indicating that treatment of DOX-loaded HAssLG
nanoparticles significantly increased fluorescence intensity
Fig. 2 TEM photographs (a, b), particle size (c, d). TEM photographs of a empty HAssLG nanoparticles and b DOX-incorporated HAssLG
nanoparticles (DOX contents, 7.8 % (w/w)). c Particle size distribution of DOX-incorporated HAssLG nanoparticles (DOX contents, 7.8 % (w/w)).
d Particle size changes of HAssLG nanoparticles according to the increase of DOX contents
Fig. 3 Fluorescence intensities (a) and fluorescence emission scan (b) of DOX-incorporated HAssLG nanoparticles according to the GSH
concentration. DOX-incorporated nanoparticles were incubated 4 h at 37 °C in the presence of GSH. Fluorescence emission spectra were
recorded in the range of 520~700 nm (excitation wavelength, 486 nm). Nanoparticle concentration was 1 mg/ml (DOX contents, 7.8 %
(w/w)). c DOX release from HAssLG nanoparticles in the presence (GSH(+), 10 mM) or absence (GSH(−), 0 mM) of GSH
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Fig. 4 a Fluorescence images of MDA-MB231 cells. MDA-MB231 cells were exposed to DOX-incorporated HAssLG nanoparticles (DOX concentration,
5 μg/ml) for 1 h. Fluorescence images of cells were observed with CLSM. The CD44 receptor of MDA-MB231 cells was blocked with free HA (0.5 mg/ml)
1 h before treatment of DOX-incorporated nanoparticles. GSH (10mM) was added to study the effect of redox-responsive delivery of nanoparticles.
b Flow cytometry analysis of MDA-MB231 cells
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creased fluorescence intensity of cells, and GSH addition
increased fluorescence intensity of cells again. These re-
sults clearly supported Fig. 3a. Figure 5 shows the antican-
cer activity of nanoparticles against MDA-MB231 cells. As
shown in Fig. 5, viability of MDA-MB231 cells was grad-
ually decreased according to the increase of DOX concen-
tration. Interestingly, HAssLG nanoparticles showed higher
anticancer activity against MDA-MB231 cells, i.e., viability
of cells with treatment of HAssLG nanoparticles was lower
than that of DOX alone. Furthermore, cell viability with
treatment of HAssLG nanoparticles was increased when
free HA was pretreated as shown in Fig. 5b. These results
indicated that HAssLG nanoparticles have enhanced anti-
cancer activity with CD44 receptor targetability.
In Vivo Animal Imaging Study
To prove the CD44 receptor-mediated delivery capacity of
HAssLG nanoparticles in vivo, CD44-positive MDA-MB231
cells and CD44-negative NIH3T3 cells were implanted into
the right flank and left flank of the mice, respectively. NIR-
dye-conjugated HAssLG nanoparticles were administered
intravenously via the tail vein of mice, and distribution of
nanoparticles in mice was observed with NIR imaging
equipment as shown in Fig. 6. As shown in Fig. 6, fluores-
cence intensity of the MDA-MB231 tumor mass was signifi-
cantly higher than that of the solid mass of NIH3T3. And
then, these differences were increased 24 h after nanoparti-
cle administration. As shown in Fig. 6b, fluorescence obser-
vation of each organ showed that the solid tumor of MDA-
MB231 cells expressed stronger fluorescence intensity than
that of NIH3T3 cells even though the liver also expressed
strong fluorescence intensity. These results indicated thatHAssLG nanoparticles have drug targeting potential against
solid tumor via a specific pathway.
Discussion
HA is a linear polysaccharide composed of D-glucuronic
acid/N-acetyl-D-glucosamine units and has a vital role in
the physiological phenomenon of cells such as adhesion,
growth, migration, cell motility, inflammation, and invasion
[31–36]. Especially, specific receptors for HA such as CD44
and RHAMM are frequently overexpressed in cancer cells
rather than normal cells [11–18]. In addition to these find-
ings, the fact that HA has biocompatibility, biodegradability,
and functional moiety such as carboxylic acid stimulates ap-
plication of HA in the biomedical field and drug targeting
research [8, 19–25]. Hyung et al. reported that HA-
decorated nanoparticles on the surface effectively targeted
the CD44 receptor of CD44-overexpressed cells rather than
lower CD44-expressed cells, while pure PLGA nanoparticles
did not show targeting differences in both cells [7]. Since in-
vasive cancer cells generally plentifully secreted hyaluroni-
dase, anticancer agent release and delivery can be stimulated
at invasive cancer cells and then specifically attack these
cells through accelerated drug release by hyaluronidase [8].
Meanwhile, redox-responsive drug delivery has been
also widely investigated for targeted drug delivery to
tumor [26, 28, 29, 37]. Disulfide bond, which is abundant
in the peptide and protein, can be cleaved by an intracellu-
lar reducing molecule, GSH, while it is stable at the extra-
cellular environment [30]. Furthermore, the GSH level in
the intracellular compartment (~10 mM) is known to be
elevated compared to that in the extracellular environ-
ment (~10 μM). Especially, GSH level is elevated in the
tumor cells [38]. These findings facilitated intracellular
Fig. 5 a Cytotoxicity of free DOX or DOX-incorporated HAssLG nanoparticles against MDA-MB231 cells. DOX or DOX-incorporated nanoparticles
were exposed to cells 24h. b. Cytotoxicity of DOX-incorporated nanoparticles in the presence (+) or absence (-) of free HA against MDA-MB231
cells (*p < 0.05). MDA-MB231 cells were pretreated with free HA 1 h before drug treatment, and then cells were exposed to 50 μg/ml of DOX or
nanoparticles for 4 h. Twenty-four hours later, viable cells were determined using the MTT assay
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bond in the polymer chain [27, 37]. Sun et al. synthesized
a diblock copolymer having a disulfide bond between dex-
tran and poly(ε-caprolactone), and then drug release rate
was increased through cleavage of disulfide bond by GSH
[37]. These phenomena enabled nanovehicles to target the
intracellular compartment.
Our concept is to attain sequential targeting of tumor
cells as shown in Fig. 7, i.e., nanoparticles are accumu-
lated in the tumor tissue by the EPR effect and then they
target tumor cells by specific interaction with the CD44
receptor on the tumor cell membrane followed by
receptor-mediated endocytosis of them. Then, GSH inthe cytosol cleaved the HA outer shell of HAssLG nano-
particles, and DOX release would be facilitated in the
intracellular environment. This hypothesis was proved
by fluorescence intensity measurement of DOX-loaded
HAssLG nanoparticles in the presence of GSH as shown
in Fig. 3a, b. Fluorescence intensity of DOX was dose-
dependently increased by GSH, indicating that GSH
cleaved the HA outer shell of the nanoparticles and then
drug release rate was promoted as shown in Fig. 3c. Fur-
thermore, CD44 receptor-specific endocytosis of nano-
particles was observed and, otherwise, CD44 receptor
blocking is to interrupt cellular uptake of nanoparticles
as shown in Fig. 4a. Furthermore, DOX delivery into the
Fig. 6 a Fluorescence imaging of MDA-MB231 cell-bearing (right flank) and NIH3T3 cell-bearing (left flank) mice. b. Organ-distribution of nanoparticles
24h later. 1 × 106 MDA-MB231 cells and NIH3T3 cells were implanted into the right flank and left flank of BALb/C nude mice (5 weeks, 20~25 g),
respectively. Three weeks later, NIR-dye-conjugated HAssLG nanoparticles (10 mg/kg) were intravenously injected via the tail vein. The major organs
of the mice were taken 24 h after nanoparticle administration
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even though the CD44 receptor of tumor cells was blocked
and nanoparticle uptake was inhibited, indicating that DOX
release was facilitated by GSH addition and subsequent
cleavage of the HA outer shell. CD44 receptor specificity of
HAssLG nanoparticles was also proved by an in vivo ani-
mal NIR fluorescence imaging study as shown in Fig. 6. To
prove the specificity of HAssLG nanoparticles, CD44-
positive MDA-MB231 cells and CD44-negative NIH3T3
mouse fibroblast cells were simultaneously implanted into
the right flank and left flank of the mice, respectively, and
then the solid tumor was prepared. As shown in Fig. 6, NIRFig. 7 Schematic illustration of tumor cell targeting using HAssLG nanoparfluorescence intensity in the back of mice was significantly
higher at tumor mass of MDA-MB231 than at solid mass
of NIH3T3, indicating that HAssLG nanoparticles specific-
ally targeted MDA-MB231 cells in vivo and they would
deliver the drug to tumor cells in a specific manner.
Conclusions
A HAssLG diblock copolymer was synthesized for applica-
tion in the sequential targeting concept of nanoparticles by
CD44 receptor-mediated and redox-responsive drug deliv-
ery. HAssLG nanoparticles have spherical shapes with nano-
sized diameter. DOX-loaded HAssLG nanoparticles wereticles
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by addition of GSH, indicating that the disulfide bond
of HAssLG nanoparticles was cleaved and then DOX
release rate was increased. In an in vitro cell culture
study, DOX-loaded HAssLG nanoparticles were endo-
cytosed by CD44 receptor-mediated pathway. An ani-
mal NIRF imaging study also proved that HAssLG
nanoparticles were delivered to tumor tissues through a
targeting mechanism. We suggest that HAssLG nano-
particles are a promising candidate for tumor targeting.
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